Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome
Open Access
- 24 June 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 115 (25), 5164-5169
- https://doi.org/10.1182/blood-2010-01-263145
Abstract
Autoimmune lymphoproliferative syndrome (ALPS) is characterized by childhood onset of lymphadenopathy, hepatosplenomegaly, autoimmune cytopenias, elevated numbers of double-negative T (DNT) cells, and increased risk of lymphoma. Most cases of ALPS are associated with germline mutations of the FAS gene (type Ia), whereas some cases have been noted to have a somatic mutation of FAS primarily in their DNT cells. We sought to determine the proportion of patients with somatic FAS mutations among a group of our ALPS patients with no detectable germline mutation and to further characterize them. We found more than one-third (12 of 31) of the patients tested had somatic FAS mutations, primarily involving the intracellular domain of FAS resulting in loss of normal FAS signaling. Similar to ALPS type Ia patients, the somatic ALPS patients had increased DNT cell numbers and elevated levels of serum vitamin B12, interleukin-10, and sFAS-L. These data support testing for somatic FAS mutations in DNT cells from ALPS patients with no detectable germline mutation and a similar clinical and laboratory phenotype to that of ALPS type Ia. These findings also highlight the potential role for somatic mutations in the pathogenesis of nonmalignant and/or autoimmune hematologic conditions in adults and children.Keywords
This publication has 37 references indexed in Scilit:
- Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndromeJournal of Allergy and Clinical Immunology, 2010
- Membrane-bound Fas ligand only is essential for Fas-induced apoptosisNature, 2009
- Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndromeBritish Journal of Haematology, 2009
- Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)Pediatric Blood & Cancer, 2009
- NRAS mutation causes a human autoimmune lymphoproliferative syndromeProceedings of the National Academy of Sciences of the United States of America, 2007
- Standard Mutation Nomenclature in Molecular Diagnostics: Practical and Educational ChallengesThe Journal of Molecular Diagnostics, 2007
- HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia)Clinical Immunology, 2006
- Somatic Mutations — Not Just for Cancer AnymoreNew England Journal of Medicine, 2004
- Autoimmune Lymphoproliferative Syndrome with SomaticFasMutationsNew England Journal of Medicine, 2004
- Immunophenotyping of blood lymphocytes in childhoodReference values for lymphocyte subpopulationsThe Journal of Pediatrics, 1997